Gene editing and gene therapy platform to treat rare genetic diseases.
(NASDAQ: FIXX)
(NASDAQ: FIXX)
Location: United States, Massachusetts, Bedford
Employees: 51-200
Total raised: $187M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Vida Ventu... | vidaventur... |
| - | 5AM Ventur... | 5amventure... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.11.2020 | - | $60M | - |
| 03.08.2017 | Series B | $83.5M | - |
| 02.05.2016 | Series A | $43.5M | - |
Mentions in press and media 23
| Date | Title | Description |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the c... |
| 21.10.2021 | Homology Medicines : 10/21/2021 Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting | - Data Support PKU and Hunter Syndrome Clinical Trials and PNH Program - BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinic... |
| 20.10.2021 | Homology Medicines : 10/20/2021 Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Societ... | - Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of JuMPStart and pheEDIT Trials - BEDFORD, Mass., October 20, 2021 - Homology Medicines, Inc. (Nasdaq: FIXX), a geneti... |
| 12.10.2021 | Homology Medicines : 10/12/2021 Homology Medicines Announces World's First Gene Editing Clinical Trial for PKU | - IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - - Company Provides Update on Enrollment in Ongoing pheNIX Trial of HMI-102 Gene Therapy for ... |
| 13.05.2021 | HOMOLOGY MEDICINES, INC. Homology Medicines : 05/13/2021 Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society ... | - Data From New GTx-mAb Platform Demonstrated Proof of Principle for AAVHSCs to Deliver One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model - - Additional Data for HMI-203 Gene Therapy in Hunter Syndrome and HMI-10... |
| 06.05.2021 | HOMOLOGY MEDICINES, INC. Homology Medicines : 05/06/2021 Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights | - On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End - - Announced New GTx-mAb Platform With Proof of Concept Data to Be Presented at Upcoming ASGCT Annual Meeting - - Presented Data Demonstrating Nuclease-Fr... |
| 07.04.2021 | HOMOLOGY MEDICINES, INC. Homology Medicines : 04/07/2021 Homology Medicines Announces Pricing of Public Offering of Common Stock | BEDFORD, Mass., April 7, 2021 - Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for proceeds of approximately $50.0 million, before deductin... |
| 01.03.2021 | Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform | - Company plans to continue advancing ophthalmic program toward a development candidate for lead indication - BEDFORD, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines com... |
| 09.11.2020 | Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc. | - |
| 13.11.2017 | Novartis co-opts Homology's gene-editing tech for R&D pipeline | In the latest move to build up Novartis’ eye drug pipeline, the pharma giant is sinking fresh capital into a gene editing company to work on secret targets in ophthalmology. Financial details weren’t disclosed, but we ... |
Show more